TMEM230

Across TCGA pan-cancer cohorts, TMEM230 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMEM230 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM230 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM230 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where TMEM230 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.698	1.000	.020	22	view →
LSCC	DFS	Quartile	All	0.916	1.000	.022	3	view →
PDAC	OS	Median	IV	0.540	0.934	.038	3	view →
GBM	DFS	Quartile	All	0.842	0.611	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMEM230–HNSC (DFS)

Open the HNSC breakdown →